Home » Topics » Cardiovascular and Metabolic Disorders »
Lipids and Cholesterol
Older adults have an increased risk for myocardial infarction and ASCVD in association with elevated levels of LDL cholesterol; and LDL-lowering therapies are effective for reducing cardiovascular events in older adults.
A clinical practice guideline was released by the Endocrine Society providing guidance for the treatment of dyslipidemia in those with endocrine diseases.
High-density lipoprotein cholesterol efflux capacity may be impaired in patients with severe short-term hypothyroidism.
The multicenter, double-blind, placebo-controlled HAUSER-RCT study assessed the efficacy and safety of evolocumab in 157 patients aged 10 to 17 years with HeFH.
Metabolic syndrome (MetS) is associated with a lethal outcome for patients with COVID-19.
The post-hoc analysis included 2 placebo-controlled phase 3 studies (ORION-10 and -11) that evaluated the efficacy and safety of inclisiran sodium in more than 2300 adult patients.
Elevated plasma levels of lipoprotein(a) and family history of coronary heart disease (CHD) were found to be associated with a risk for cardiovascular disease.
Researchers used electronic health records to further understand the clinical features and gaps in treatment approaches for patients with severe hypercholesterolemia.
Pitavastatin lowers blood total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides in a dose-dependent manner.
Evinacumab is an investigational fully-human monoclonal antibody that binds to and blocks the function of angiopoietin-like 3 (ANGPTL3).
The treatment of patients with familial hypercholesterolemia and COVID-19 with dyslipidemia medications may prevent the occurrence of thrombotic events.
Want to read more?
Please login or register first to view this content.